Tony S. Mok, MD

home / authors / tony-s-mok-md

Articles

Tony S. Mok, MD, Reviews Importance of Adjuvant Nivolumab in Resectable NSCLC

Tony S. Mok, MD

July 25th 2022

Tony S. Mok, MD, spoke about utilizing adjuvant or neoadjuvant treatment for patients with non–small cell lung cancer.

Tony S. Mok, MD, Talks Future Analyses of Capmatinib Plus Pembrolizumab in NSCLC

Tony S. Mok, MD

July 5th 2022

Tony S. Mok, MD, spoke about future research efforts focused on capmatinib plus pembrolizumab in patients with previously untreated MET-unselected, PD-L1–positive non–small cell lung cancer.

Tony S. Mok, MD, Reviews Capmatinib Plus Pembrolizumab in Previously Untreated NSCLC

Tony S. Mok, MD

June 15th 2022

Tony S. Mok, MD, spoke about the use of capmatinib plus pembrolizumab in patients with previously untreated non–small cell lung cancer who were MET unselected and had PD-L1 expression of 50% or more.